Track market-moving stories before they get noisy

CFS Investment Advisory Services LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 144.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,451 shares of the medical instruments supplier’s stock after purchasing an additional 3,815 shares during the quarter. CFS Investment Advisory Services LLC’s holdings in Becton, Dickinson and Company were worth $1,155,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ramsay Stattman Vela & Price Inc. increased its holdings in Becton, Dickinson and Company by 2.1% in the 3rd quarter. Ramsay Stattman Vela & Price Inc. now owns 28,077 shares of the medical instruments supplier’s stock worth $5,026,000 after purchasing an additional 590 shares in the last quarter. Novem Group acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $225,000. Value Partners Investments Inc. grew its position in shares of Becton, Dickinson and Company by 13.7% during the 3rd quarter. Value Partners Investments Inc. now owns 10,121 shares of the medical instruments supplier’s stock worth $1,815,000 after buying an additional 1,218 shares during the period. AA Financial Advisors LLC bought a new stake in Becton, Dickinson and Company in the third quarter valued at $204,000. Finally, James Hambro & Partners LLP increased its position in Becton, Dickinson and Company by 13.4% in the 3rd quarter. James Hambro & Partners LLP now owns 335,229 shares of the medical instruments supplier’s stock valued at $60,026,000 after buying an additional 39,543 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 1.6% NYSE BDX opened at $193.77 on Wednesday. The company has a market capitalization of $53.39 billion, a price-to-earnings ratio of 58.36, a PEG ratio of 12.86 and a beta of 0.21. The stock’s 50-day simple moving average is $184.51 and its two-hundred day simple moving average is $164.26. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $195.99.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the business earned $3.68 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year. Becton, Dickinson and Company Announces Dividend The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Insider Transactions at Becton, Dickinson and Company In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 6,906 shares of company stock worth $1,265,855. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In Several research analysts have weighed in on BDX shares. Bank of America upped their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Finally, Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $185.07.

View Our Latest Analysis on Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Read More Five stocks we like better than Becton, Dickinson and Company Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Birch Hill Investment Advisors LLC raised its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 862.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,321 shares of the medical instruments supplier’s stock after purchasing an additional 19,106 shares during the quarter. Birch Hill Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $3,816,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Auto Owners Insurance Co lifted its stake in Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the last quarter. BlackRock Inc. purchased a new position in Becton, Dickinson and Company during the 2nd quarter worth $3,721,533,000. State Street Corp grew its holdings in Becton, Dickinson and Company by 8.5% during the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after acquiring an additional 1,177,256 shares during the period. First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after buying an additional 1,887,224 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the second quarter worth $474,993,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.3% NYSE:BDX opened at $191.34 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $195.99. The stock’s 50 day moving average price is $184.03 and its 200 day moving average price is $163.70. The company has a market capitalization of $52.72 billion, a P/E ratio of 57.63, a P/E/G ratio of 12.93 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year. Becton, Dickinson and Company Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Analysts Set New Price Targets Several equities research analysts have issued reports on the stock. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Bank of America lifted their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $185.07.

Check Out Our Latest Stock Analysis on Becton, Dickinson and Company

Insider Buying and Selling at Becton, Dickinson and Company In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is currently owned by corporate insiders.

(Free Report)

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

Featured Articles Five stocks we like better than Becton, Dickinson and Company Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways BD's Revello stent met the AGILITY trial's nine-month primary endpoint, with a failure rate of just 2.8%.Trial showed 97.2% primary patency and 98.3% freedom from clinically driven target lesion revascularization.BD's Revello stent remains investigational in the U.S., with clinical follow-up continuing through 36 months. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently reported positive nine-month results from the iliac cohort of the AGILITY trial evaluating its Revello Vascular Covered Stent for treating iliac artery disease, a form of peripheral artery disease (PAD). The findings, presented at VIVA 2026, showed promising safety and effectiveness and support continued clinical evaluation of the device.

The results are encouraging for BD as it seeks to strengthen its position in the peripheral vascular market through product innovation and clinical evidence. If subsequent follow-up confirms the device’s durability and effectiveness, Revello could expand BD’s growth opportunities in vascular intervention. Although Revello is CE-marked, it remains under clinical development in the United States and is limited to investigational use under U.S. law. Its commercial potential will depend on further clinical results and regulatory progress.

BDX Stock Trend Following the NewsFollowing the announcement on Oct. 7, BDX stock has gained more than 2% till yesterday’s close. Year to date, shares of the company have lost 2.7% against the industry’s 9.5% growth and the S&P 500’s 12.5% rise.

The positive AGILITY trial results could support BDX’s long-term growth by strengthening its portfolio of peripheral vascular intervention products and expanding clinical evidence for the Revello Vascular Covered Stent. Favorable outcomes may improve physician confidence in the device and support its adoption if it secures the necessary regulatory approvals.

This could create an additional growth opportunity for BD in treating peripheral artery disease while complementing its broader vascular portfolio. However, long-term revenue contribution will depend on the completion of clinical follow-up, regulatory clearance in the United States and the device’s eventual commercial uptake.

BDX currently has a market capitalization of $51.63 billion.

Image Source: Zacks Investment Research

AGILITY Trial Demonstrates Strong Safety and EffectivenessBD’s AGILITY Investigational Device Exemption trial evaluated the Revello Vascular Covered Stent in patients with iliac artery disease, which can restrict blood flow to the legs and feet, causing pain, cramping and reduced mobility. The iliac cohort enrolled 120 patients across 28 investigational sites in the United States, Europe, Australia and New Zealand. At nine months, the study met its primary composite safety and effectiveness endpoint, with a failure rate of just 2.8%, well below the prespecified performance goal of 19%.

The results also showed 97.2% primary patency, indicating that the treated arteries remained open. Trial data also demonstrated 98.3% freedom from clinically driven target lesion revascularization, suggesting a low need for repeat procedures due to clinical symptoms. Additionally, there were no device- or procedure-related deaths, no major amputations in the target limb at or above the ankle, or unanticipated serious adverse device effects. These findings support the stent’s performance in treating iliac artery disease, including cases involving moderate-to-severe lesion calcification.

Revello Stent Advances BD’s Peripheral Vascular PortfolioThe Revello Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with radial resistive force tailored to the iliac arteries. Beyond safety and vessel patency, patients treated in the AGILITY trial showed improvements in disease severity and walking ability. The mean Rutherford category, a measure of peripheral artery disease severity, improved from 3.0 at baseline to 0.3 at nine months, while the mean Walking Impairment Questionnaire score increased by 31.7 points.

Women accounted for approximately 41% of enrolled patients, adding to the diversity of the study population. Clinical follow-up in the iliac cohort will continue through 36 months to assess the durability of the results. BD also completed enrollment in the trial’s superficial femoral and proximal popliteal artery cohort in August 2026, extending the study’s evaluation of the device across additional peripheral vascular applications.

Continued positive results and progress toward regulatory approval could strengthen BD’s competitive position in peripheral intervention, although broader commercial adoption will depend on longer-term clinical outcomes and regulatory developments.

Industry Prospects Favoring the MarketGoing by data provided by Grand View Research, the global iliac stent market size was valued at $1.2 billion in 2025 and is projected to grow from $1.3 billion in 2026 to $2 billion by 2033, at a CAGR of 6.5% from 2026 to 2033.

Growth of the market can be attributed to growing advancements in medical technology, increasing prevalence of peripheral artery diseases and expanding awareness about minimally invasive procedures as an effective treatment option.

Other NewsBD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

YHB Investment Advisors Inc. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 134.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,874 shares of the medical instruments supplier’s stock after purchasing an additional 5,089 shares during the period. YHB Investment Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $1,588,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. BlackRock Inc. bought a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $3,721,533,000. State Street Corp grew its holdings in shares of Becton, Dickinson and Company by 8.5% in the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after acquiring an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC increased its position in shares of Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares during the last quarter. Auto Owners Insurance Co raised its holdings in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the second quarter valued at approximately $474,993,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance NYSE:BDX opened at $182.54 on Friday. The company has a market cap of $50.30 billion, a P/E ratio of 54.98, a P/E/G ratio of 12.15 and a beta of 0.21. The firm’s fifty day moving average price is $181.98 and its two-hundred day moving average price is $162.38. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year. Becton, Dickinson and Company Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insiders Place Their Bets In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,906 shares of company stock worth $1,265,855 in the last quarter. 0.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In A number of brokerages have recently issued reports on BDX. Bank of America upped their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Wednesday. They issued an “underweight” rating and a $165.00 target price for the company. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $185.07.

Check Out Our Latest Report on BDX

(Free Report)

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

See Also Five stocks we like better than Becton, Dickinson and Company Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Physicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirth and giving babies a healthier start in life.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, the Global Surgery Foundation (GSF) and the Business Council for International Understanding (BCIU) brought together healthcare, government, academia, and industry leaders to advance solutions aimed at reducing maternal mortality worldwide. On the sidelines of the 81st United Nations General Assembly (UNGA), participants explored how continuous noninvasive blood pressure monitoring and advanced hemodynamic insights, can help clinicians identify complications earlier, respond faster and improve care for mothers and their babies.

BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide World Health Leaders have called for accelerated maternal safety action to meet the United Nations Sustainable Development Goal of reducing the global maternal mortality ratio to fewer than 70 deaths per 100,000 live births by 2030. The latest UN data put the global ratio at 197 deaths per 100,000 live births in 2023, with approximately 260,000 women dying from pregnancy-related causes that year – one every two minutes, substantially above the global goal.

To address the shortfall, offer detailed solutions and create situational awareness of the upcoming deadline, a high-level panel discussion was convened at the Japan Society on the sidelines of UNGA on September 24, focused on "Advancing Maternal Safety During Childbirth: Improving Recognition, Response and Care." 

"We have an opportunity to help clinicians recognize risks earlier, respond faster and make more informed decisions during childbirth," said Tim Patz, worldwide president of Advanced Patient Monitoring at BD. "Advanced hemodynamic monitoring can help give mothers and babies a safer chance at a healthy outcome."

Expert speakers at the event included:

Jean Chamberlain, M.D., Professor, Obstetrics & Gynecology, Clinical Consultant McMaster University; Member of the Order of Canada Geoff Ibbotson, M.D., Executive Director, The Global Surgery Foundation Latoya Mason, M.D., Director of Obstetric Anesthesia Education at the University of Mississippi Medical Center. Michael Scott, M.D., chair of the Department of Anesthesiology and Perioperative Medicine at the University of Rochester Medical Center. Professor Katsuo Terui, M.D., PhD, Department Head and Professor at Saitama Medical University. "Every mother deserves care that recognizes deterioration early, regardless of where she delivers, the resources available, or whether a clinician happens to be at the bedside at the critical moment," said Dr. Mason. After the birth of her second child, she developed peripartum cardiomyopathy, heart failure specific to pregnancy. She received the care she needed and is now working to ensure that others in her community have access to the same life-saving care.

Participants agreed that accelerating progress toward the UN's 2030 maternal mortality target will require stronger collaboration, earlier recognition of complications, and broader adoption of evidence-based maternal care practices, including optimized monitoring standards.

Visit Advancing Maternal Safety during Childbirth | The Global Surgery Foundation — The Global Surgery Foundation for more information and to access a recording of the event.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X  or Instagram @becton_dickinson.

Michael Scott, M.D. is a paid consultant of BD, but was not compensated by BD for providing professional services at this event.

SOURCE BD (Becton, Dickinson and Company)

Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease (PAD). The findings mark an important milestone in the efforts by BD to expand clinical evidence supporting innovative solutions for chronic vascular disease and reinforce its commitment to advancing care for patients with PAD.

New AGILITY trial data presented at VIVA 2026 reinforce BD’s commitment to advancing peripheral vascular care. Nine-month results from the iliac cohort showed strong safety and effectiveness outcomes for the Revello™ Vascular Covered Stent, including 97.2% primary patency and 98.3% freedom from clinically driven target lesion revascularization. Together, these findings expand the growing body of evidence supporting innovative treatment options for patients with PAD. The study met its primary composite endpoint for the treatment of iliac artery disease and adds to the growing body of clinical evidence supporting the continued evaluation of the Revello™ Vascular Covered Stent. The device is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries.

Iliac artery disease can reduce blood flow to the legs and feet and potentially cause symptoms such as leg pain, cramping, impaired mobility and reduced quality of life. As treatment options evolve, physicians continue to seek durable solutions that provide sustained vessel patency and favorable long-term outcomes, particularly for patients with complex iliac artery anatomy.

The AGILITY iliac cohort enrolled 120 patients at 28 investigational sites in the United States, Europe, Australia and New Zealand. Through nine months of follow-up, treatment with the Revello™ Vascular Covered Stent resulted in:

Composite safety and effectiveness endpoint met with a failure rate of 2.8%, significantly below the 19% prespecified performance goal 97.2% primary patency 98.3% freedom from clinically driven target lesion revascularization No device- or procedure-related deaths, target limb major amputations (at or above the ankle), or unanticipated serious adverse device effects Patients experienced meaningful gains in daily function and mobility, with mean Rutherford category improving from 3.0 at baseline to 0.3 and mean WIQ score improving by 31.7 points from baseline to 9 months. Women represented approximately 41% of enrolled patients, and slightly more than half of lesions showed moderate-to-severe calcification.

"These latest data showed high primary patency and low clinically driven target lesion revascularization in a patient population that included both straightforward and complex iliac lesions," said Sean Lyden, M.D., chairman of the Department of Vascular Surgery at Cleveland Clinic and global lead principal investigator for AGILITY. "Results showed the treated arteries remained open in a high percentage of patients, and at nine months, patients also showed changes in disease severity and walking ability."

"These results reflect the continued commitment of BD to advance evidence-based innovation in peripheral vascular care," said Rob Righi, vice president and general manager of the Vascular Platform, Peripheral Intervention at BD. "As follow-up continues, the AGILITY study will help further characterize the Revello™ Vascular Covered Stent's performance across patients with peripheral artery disease."

Clinical follow-up in the iliac cohort is ongoing through 36 months. BD also completed enrollment in the study's superficial femoral and proximal popliteal artery cohort this past August, marking another milestone in the AGILITY study.

The Revello™ Vascular Covered Stent is CE marked. In the United States, the Revello™ Vascular Covered Stent is an investigational device limited by U.S. law to investigational use only.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

Generations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the world

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn., the birthplace of the world's first fully sterile, single-use disposable plastic syringe and the largest syringe manufacturing operation in the United States.

BD, a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn.

The BD Canaan site opened in 1961 with eight employees in a 25,000-square-foot building. Today, more than 500 employees work at the 385,000-square-foot facility, producing more than 2 billion syringes each year. The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. The invention of the BD® Syringe helped enable the shift away from reusable glass syringes, reducing the risk of patient-to-patient disease transmission.

Today, more than 500 employees work at the 385,000-square-foot facility, producing more than 2 billion syringes each year, supporting care from routine vaccinations to critical procedures. Over six decades, the Canaan team has supported major public health efforts, including smallpox eradication, H1N1 vaccination programs and the COVID-19 response.

"The BD® Syringe was invented here in Canaan as a breakthrough in patient safety and has become an essential part of care around the world, touching 80 patients every second," said Eric Borin, worldwide president, Medication Delivery Solutions at BD. "For 65 years, generations of employees have continued to improve how we manufacture while delivering the quality and precision clinicians count on. This milestone is a testament to their dedication and the difference their work makes for patients every day."

BD has invested more than $34 million in the Canaan site over the past five years to expand production capacity, modernize operations and support future growth. This includes three new syringe manufacturing lines and equipment upgrades that strengthen supply assurance. These investments reflect BD's commitment to U.S. manufacturing and to helping healthcare systems maintain reliable access to high-quality medical technologies.

"Connecticut has a proud history of turning innovation into products that improve people's lives, and BD's Canaan facility is a powerful example," said Governor Ned Lamont. "For 65 years, this site has supported good jobs, strengthened our manufacturing economy and produced medical devices used in patient care around the world. BD's continued investment in Canaan demonstrates the strength of Connecticut's workforce and the important role our state plays in manufacturing essential healthcare products."

A Connecticut legacy with global reach
BD leaders, elected officials, employees and community partners gathered at the Canaan facility to celebrate its 65-year history and contributions to healthcare, manufacturing and the regional economy. That legacy is reflected in the generations of employees who have built careers at the site. More than 50 have at least 25 years of service, including 10 who have been with BD for 40 years or more.

"BD has been an important part of northwestern Connecticut for 65 years, providing local jobs while manufacturing a product that supports patient care around the world," said State Representative Maria Horn and State Senator Stephen Harding in a joint statement. "The Canaan facility shows how advanced manufacturing can create meaningful opportunities in our communities while making a difference far beyond our state. We congratulate the employees who have made this milestone possible and welcome BD's continued investment in the region."

As part of the celebration, BD will announce a $10,000 grant to the Community Health & Wellness Center, a Federally Qualified Health Center that provides accessible, high-quality healthcare to residents of northwestern Connecticut. The grant brings BD's support since 2024 to $90,000 helping fund nutrition programs, emergency assistance and transportation for patients in need. The partnership reflects BD's longstanding commitment to strengthening the communities where employees live and work.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worldwide president of the Surgery business unit at BD, effective immediately.

Abuzaina will be responsible for driving the global strategic, operational, and commercial performance of Surgery. He will be based out of BD Surgery's headquarters in Warwick, RI, and will report to Peter Menziuso, executive vice president and president of the Interventional segment.

BD Appoints Ferass Abuzaina as Worldwide President of Surgery "Surgery is well-positioned for its next chapter of growth, and Ferass is the right leader to help us build on that momentum," said Menziuso. "He combines a deep understanding of our business with a strong commitment to innovation, execution and serving customers. I am confident his leadership will help us continue advancing solutions that improve outcomes for patients and clinicians around the world."

Abuzaina currently serves as Worldwide VP/GM, Advanced Repair and Reconstruction, within Surgery. He joined BD in 2013 and has held leadership positions across multiple BD businesses, with experience spanning research and development, strategy and business development. Abuzaina has played an important role in advancing Surgery's innovation pipeline, commercial excellence and operational performance.

He earned a Bachelor of Science, Master of Science and Ph.D. in Chemical Engineering from New York University's Tandon School of Engineering, as well as a Master of Business Administration from the University of Connecticut School of Business.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X   or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

Park National Corp OH cut its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 18.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 48,535 shares of the medical instruments supplier’s stock after selling 10,859 shares during the period. Park National Corp OH’s holdings in Becton, Dickinson and Company were worth $8,688,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Waterhouse Canada Inc. grew its position in shares of Becton, Dickinson and Company by 17.1% during the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock worth $14,715,000 after acquiring an additional 14,077 shares during the last quarter. Northside Capital Management LLC grew its holdings in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after buying an additional 9,494 shares in the last quarter. NewEdge Advisors LLC raised its stake in Becton, Dickinson and Company by 35.0% during the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after acquiring an additional 11,414 shares in the last quarter. Beverly Hills Private Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter worth $3,353,000. Finally, Wealthfront Advisers LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at $2,567,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 in the last 90 days. 0.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth Several brokerages have recently issued reports on BDX. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Bank of America boosted their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Finally, Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $187.67. Read Our Latest Research Report on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Performance Becton, Dickinson and Company stock traded up $2.61 during midday trading on Monday, hitting $179.41. 478,562 shares of the company were exchanged, compared to its average volume of 2,505,086. The business has a fifty day simple moving average of $180.69 and a two-hundred day simple moving average of $161.72. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The firm has a market capitalization of $49.43 billion, a PE ratio of 54.03, a price-to-earnings-growth ratio of 11.92 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

(Free Report)

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

Further Reading Five stocks we like better than Becton, Dickinson and Company A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You?

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways BDX is advancing its pure-play MedTech strategy around execution, innovation and efficiency.BDX has achieved $150M of its $200M cost-out program, supporting profitability and cash flow generation.Becton, Dickinson faces reimbursement uncertainty, macroeconomic pressure, competition and FX exposure. Becton, Dickinson and Company (BDX - Free Report) is benefiting from its focused transformation into a pure-play MedTech company, supported by strong execution of its BD 2025 strategy. The company’s continued emphasis on innovation, strategic partnerships and solid third-quarter fiscal 2026 results are driving optimism. However, persistent reimbursement uncertainties, macroeconomic headwinds and stiff competition remain key concerns.

This Zacks Rank #3 (Hold) stock has lost 5.3% in the year-to-date period against the industry’s 2% growth. The S&P 500 Composite has returned 12.7% during the same time frame.

The renowned medical technology player, with a market capitalization of $50.65 billion, remains focused on delivering durable growth and margin expansion. It projects 5.2% growth for the next fiscal year and expects to maintain a strong performance in the future. BDX’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, with the average being 2.9%.

Image Source: Zacks Investment Research

Reasons Favoring BDX’s GrowthStrategic Execution Under the New BD Framework: Following the separation of its Biosciences and Diagnostic Solutions business and combination with Waters, the company is executing its New BD strategy as a focused MedTech company. The company’s priorities — Compete, Innovate and Deliver — are aimed at strengthening commercial execution, accelerating innovation and improving operational efficiency. Management remains focused on driving sustainable growth, margin expansion and long-term shareholder value.

The strategy is already yielding results. In second-quarter fiscal 2026, more than 90% of Becton, Dickinson’s portfolio delivered mid-single-digit growth, while key growth platforms such as biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration posted double-digit gains. The company has also achieved $150 million of its $200-million cost-out program, supporting profitability and cash flow generation.

Continued Focus on Innovation and R&D: BD's long-term growth strategy is driven by innovation and new product development, backed by investments in R&D, clinical trials and regulatory approvals. The company conducts R&D through its operating units and global centers of excellence across the United States, India, China, Singapore and Ireland while collaborating with academic and clinical institutions to accelerate innovation. In August, BD completed enrollment in the 477-patient PREVENT clinical trial across 32 sites in the United States and Europe, evaluating Phasix Mesh for preventing incisional hernias, with the primary endpoint set at 24 months and follow-up extending to five years.

Strategic Partnerships: BD continues to advance its portfolio transformation through strategic collaborations and transactions aimed at expanding its presence in higher-growth MedTech markets. In July, the company partnered with Brazilian pharmaceutical firm EMS to launch a semaglutide therapy in Brazil using BD's Vystra Injection Pen platform, strengthening its exposure to the growing GLP-1 drug-delivery market.

Earlier in February, BD completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation through a Reverse Morris Trust transaction, retaining a 39.2% stake in the combined company while receiving a $4 billion cash distribution, half of which funded share repurchases and the remainder reduced debt. The transaction also streamlined BD's portfolio into four core operating segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.

Factors That May Offset BDX’s GainsMacroeconomic Headwinds: BDX faces risks from inflation, tariffs, supply-chain disruptions and geopolitical uncertainties. Persistent cost pressures and changes in global trade policies could increase operating expenses, disrupt production and weigh on healthcare spending.

Reimbursement Challenges: Demand for the company’s products depends partly on reimbursement policies and insurance coverage. Increasing pricing scrutiny, value-based payment reforms and healthcare budget constraints may limit product adoption, pressure pricing and reduce procedure volumes.

Intense Competition & Foreign Exchange Exposure: Becton, Dickinson operates in a highly competitive medical technology market characterized by rapid innovation, industry consolidation and pricing pressure from low-cost manufacturers. Significant international operations expose the company to foreign currency fluctuations, which can adversely impact revenues, profitability and cash flows despite hedging efforts.

Estimate TrendBecton, Dickinson is witnessing a stable estimate revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has been unchanged at $12.59 per share.

The Zacks Consensus Estimate for the company’s fourth-quarter fiscal 2026 revenues is pegged at $5.12 billion, indicating a 13% decline from the year-ago quarter’s reported number.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice president and chief information and digital officer, effective September 30.

Arthur (Art) Hu, Executive Vice President and Chief Information and Digital Officer, BD Hu brings more than 25 years of experience leading global technology, digital and business transformation initiatives at scale. He joins BD from Lenovo Group, where he most recently served as senior vice president, global chief information officer and chief technology and delivery officer for the Solutions and Services Group. There, his responsibilities included leading digital technology, AI adoption and business transformation across customer, partner and employee-facing platforms. Prior to Lenovo, he spent over a decade at McKinsey & Company advising organizations on technology, operations, strategy and organizational transformation. Throughout his career, Hu has demonstrated the ability to connect technology to business outcomes, using digital capabilities to drive growth, improve execution and embed operational excellence.

"Art is an exceptional technology and transformation leader with a proven track record of using digital, AI and automation to drive performance at scale," said Tom Polen, chairman, CEO and president of BD. "Bringing his depth of technology-sector experience to BD strengthens our leadership team and gives us an important advantage as technology becomes increasingly central to how healthcare is delivered and how leading MedTech companies operate. Art will play a critical role in building a faster, more productive and more connected BD – modernizing our enterprise, embedding AI into how we work, and translating technology into greater innovation and stronger business outcomes. We are excited to have a leader of his caliber help shape the next chapter of BD and create even greater value for our customers, patients and shareholders.  

Hu will succeed Denise Russell Fleming, who will retire from BD at the end of 2026.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X  @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

Key Takeaways BD deployed Vmax 160 at Fairview to automate high-volume centralized outpatient pharmacy fulfillment.Vmax 160 offers overnight EasyLoad replenishment, 99.8% accuracy and three-second tote loading.Cold-chain support and smart expiry detection can cut waste, boost safety and improve inventory visibility. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.

Per management, the future of pharmacy care will ever more depend on efficient and scalable models that can meet patients’ needs while expanding access to therapies. BD believes Fairview’s investment in centralized pharmacy operations and intelligent automation demonstrates how health systems can modernize pharmacy services, improve efficiency and serve their communities better.

Likely Trend of BDX Stock Following the NewsFollowing the announcement, BDX stock gained 2.8% at yesterday’s close. Year to date, shares of the company have lost 5.8% against the industry’s 5% growth. The S&P 500 has risen 11.1% in the same timeframe.

The U.S. deployment of BD Vmax 160 could strengthen BD’s position in the expanding pharmacy automation market. As demand rises for specialty therapies, biologics, GLP-1 medications and refrigerated medicines, health systems are likely to seek automation capable of handling more complex fulfillment requirements. BD’s expanding portfolio of robotics and connected pharmacy solutions could support long-term demand, improve operational efficiency for customers and create opportunities for further adoption of its pharmacy automation technologies.

BDX currently has a market capitalization of $49 billion.

Image Source: Zacks Investment Research

More on the DeploymentBD Vmax 160 is designed specifically for centralized fulfillment environments, automating labor-intensive pharmacy workflows. Its BD EasyLoad system enables overnight inventory replenishment, with a reported three-second loading time per tote and 99.8% accuracy. Automated labeling also helps reduce manual work while supporting labeling requirements across all 50 states.

Another major capability is cold-chain support for medications requiring storage between 2°C and 8°C. The system also features smart expiry detection, which tracks expiration dates when medications are loaded and automatically prevents expired products from being dispensed. These capabilities can help pharmacies improve inventory visibility, reduce waste and strengthen medication safety.

Fairview, which fills an average of 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services in Minnesota, is the first U.S. health system to deploy the system. Fairview’s deployment builds on its existing collaboration with BD, including the BD Parata Max 2 high-speed vial filling robot. Alongside the BD Incada Connected Care Platform and other automation technologies, Vmax 160 advances BD’s broader vision of a connected, intelligent end-to-end pharmacy ecosystem.

Factors Favoring the MarketAccording to data provided by Grand View Research, the global pharmacy automation devices market is estimated to be $7.9 billion in 2026 and is expected to witness a CAGR of 7.5% through 2033.

Factors such as the rising adoption of automated dispensing systems, increasing need to improve pharmacy efficiency, growing focus on medication safety and the expanding use of centralized pharmacy operations are expected to support market growth.

Other NewsBD is advancing its advanced tissue regeneration strategy through two key clinical milestones. The company recently announced that the STANCE trial of GalaFLEX LITE Scaffold surpassed 50% of its maximum planned enrollment, with 274 patients treated across 33 U.S. sites.

BD also completed enrollment of 477 patients across 32 U.S. and European sites in the PREVENT trial evaluating Phasix Mesh for incisional hernia prevention. Both studies are designed to generate clinical evidence that could support future FDA submissions and expand the applications of BD’s regenerative technologies.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently sporting a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

On September 10, 2026, we delve into the DCF analysis for Becton Dickinson & Co BDX, a company that has shown a year-to-date price increase of 20.1%. However, the stock has experienced a recent decline of 3.5% over the past week. Here are some key points to consider:

DCF Earnings-based intrinsic value of $156.87 vs current price of $179.80 (margin of safety: -14.6%) DCF Free Cash Flow-based intrinsic value of $102.16 (significantly overvalued) GF Score™ of 66/100 indicates moderate reliability of the DCF inputs What Is BDX Worth? DCF Earnings-Based Model The DCF earnings-based model for Becton Dickinson & Co employs a two-stage approach, where we first estimate the growth in earnings per share (EPS) over the next ten years, followed by a terminal growth phase. The assumptions for this model are as follows:

Parameter Value Current EPS (TTM, excl. non-recurring) $12.99 10-Year Growth Rate 5.7% 10-Year Treasury Rate 4.86% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the first stage, we project EPS growth at 5.7% annually for ten years, discounted at a rate of 11%. In the second stage, we assume a terminal growth rate of 4% for the following ten years, also discounted at 11%. The calculation summary is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 5.7%, discounted at 11% $100.23 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $56.64 Intrinsic Value Growth + Terminal $156.87 With a current price of $179.80, BDX appears to be modestly overvalued, presenting a margin of safety of -14.6%. It is important to note that GuruFocus utilizes EPS excluding non-recurring items since research indicates a stronger correlation between stock prices and earnings than with free cash flow. For further details, you can access the BDX DCF Calculator.

What Does the Free Cash Flow DCF Say? The intrinsic value derived from the Free Cash Flow (FCF) DCF model stands at $102.16. This presents a stark contrast to the earnings-based intrinsic value of $156.87, indicating significant disagreement between the two models. The FCF-based valuation suggests that BDX is significantly overvalued, with a margin of safety of -76.0%.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Becton Dickinson & Co is calculated at $183.22, providing a third perspective on valuation. This proprietary measure from GuruFocus is derived from historical trading multiples, past business growth, and future performance estimates. The divergence among the three models—DCF earnings, DCF FCF, and GF Value™—highlights the complexity of accurately assessing BDX's valuation. For more insights, visit the GF Value™ page.

What Does BDX's GF Score™ Tell Us? The GF Score™ evaluates a company's financial health, profitability, growth potential, and valuation metrics. BDX's score of 66/100 indicates a moderate level of reliability in its financial metrics, though its predictability rank is low at 1 out of 5 stars. This low predictability suggests that the DCF model may not be as reliable for this stock. Below is a summary of BDX's GF Score™ metrics:

Metric Rating GF Score™ 66/100 Financial Strength 5/10 Profitability 8/10 Growth 4/10 Valuation 9/10 Momentum 1/10 For more details on BDX, visit the BDX stock page.

Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as BDX, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect actual future performance.

What This Means for Investors In synthesizing the insights from the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find a notable disagreement. The DCF earnings model suggests a modest overvaluation, while the FCF model indicates a significant overvaluation. In contrast, the GF Value™ presents a more favorable view, suggesting BDX is slightly undervalued. Additionally, the guru ownership signal shows that 14 gurus currently hold the stock, with 10 adding to their positions and 6 trimming their holdings over the recent quarters. However, insider activity indicates net selling of $2.9 million over the past year, which could be a cautionary signal. This mixed picture highlights the need for careful consideration before making investment decisions. For further exploration of BDX's valuation, check out the BDX DCF Calculator.

Frequently Asked Questions What is BDX's intrinsic value based on DCF?

According to the analysis, the earnings-based intrinsic value is $156.87, while the FCF-based intrinsic value is $102.16.

Is BDX overvalued or undervalued?

The consensus from the DCF and GF Value™ suggests that BDX is overvalued, with the earnings-based DCF indicating modest overvaluation and the FCF-based DCF indicating significant overvaluation.

How reliable is the DCF model for BDX?

The reliability of the DCF model for BDX is limited, as indicated by its predictability rank of 1 out of 5 stars.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

On September 02, 2026, we delve into the DCF analysis for Becton Dickinson & Co BDX , a company that has shown notable price performance with a year-to-date increase of 24.3% and a one-year rise of 26.7%. However, despite this positive momentum, our valuation models suggest a different narrative regarding its current pricing.

DCF Earnings-based intrinsic value indicates a modest overvaluation with a margin of safety of -19.3%. DCF Free Cash Flow (FCF)-based intrinsic value stands at $102.16, suggesting a significantly overvalued position with a margin of safety of -83.2%. GF Score™ of 79/100 indicates a moderate level of reliability for the DCF inputs, but with a predictability rank of 1/5 stars, caution is warranted. What Is BDX Worth? DCF Earnings-Based Model In our DCF earnings-based model, we utilize a two-stage approach to assess BDX's intrinsic value. The first stage involves a growth phase where we project earnings per share (EPS) growth at 5.7% annually for the next 10 years, followed by a terminal phase with a growth rate of 4% for the subsequent 10 years. The discount rate applied is 11%, derived from the risk-free rate and equity risk premium.

Parameter Value Current EPS (TTM, excl. non-recurring) $12.99 10-Year Growth Rate 5.7% 10-Year Treasury Rate 4.81% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the two-stage model is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 5.7%, discounted at 11% $100.23 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $56.64 Intrinsic Value Growth + Terminal $156.87 With the current price at $187.12, the intrinsic value of $156.87 indicates that BDX is modestly overvalued, reflecting a margin of safety of -19.3%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For a detailed analysis, visit the BDX DCF Calculator.

What Does the Free Cash Flow DCF Say? In contrast, the FCF-based intrinsic value for BDX is calculated at $102.16. This significant discrepancy compared to the earnings-based valuation further emphasizes the overvaluation of the stock, with a margin of safety of -83.2%. Both models align in their conclusion that BDX is overvalued, but the FCF model provides a more conservative estimate.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for BDX is calculated at $185.85, providing a third perspective on valuation. This proprietary measure from GuruFocus incorporates historical trading multiples, past business growth, and future performance estimates. All three models—DCF earnings, DCF FCF, and GF Value™—concur that BDX is overvalued, reinforcing the caution for potential investors. For more insights, check the GF Value™ page.

What Does BDX's GF Score™ Tell Us? The GF Score™ measures a company's financial health and growth potential based on various factors. BDX holds a score of 79/100, indicating a relatively strong position, but its predictability rank of 1/5 stars suggests that the DCF model may not be as reliable for this stock. Below is a summary of the GF Score™ metrics:

Metric Rating GF Score™ 79/100 Financial Strength 5/10 Profitability 8/10 Growth 4/10 Valuation 9/10 Momentum 10/10 For more information, visit the BDX stock page.

Key Assumptions and Limitations The DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Given BDX's low predictability rating, the reliability of the DCF estimates is diminished. Additionally, the terminal growth rate of 4% is a simplifying assumption that may not fully capture future market dynamics.

What This Means for Investors In synthesizing the insights from the DCF earnings model, the DCF FCF model, and the GF Value™, we find a consensus that BDX is overvalued. The guru ownership signal indicates that 14 gurus currently hold the stock, with 10 adding to their positions while 6 have trimmed their holdings. This mixed signal, combined with insider selling of $2.9M over the past 12 months, suggests caution for potential investors. For a deeper dive into the valuation, explore the BDX DCF Calculator.

Frequently Asked Questions What is BDX's intrinsic value based on DCF?

Based on our analysis, the earnings-based intrinsic value is $156.87, while the FCF-based intrinsic value is $102.16.

Is BDX overvalued or undervalued?

Both the DCF and GF Value™ models indicate that BDX is overvalued.

How reliable is the DCF model for BDX?

The DCF model's reliability is low, reflected in a predictability rank of 1/5 stars.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.

Key Takeaways BD enrolled 477 patients across 32 U.S. and European sites in the PREVENT trial.Phasix Mesh is being studied to prevent incisional hernias in high-risk abdominal surgery patients.Successful 24-month data could support BD's planned FDA submission for a new preventive indication. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently completed enrollment for its PREVENT clinical trial evaluating Phasix Mesh for preventing incisional hernias in high-risk patients undergoing elective open midline abdominal surgery.

For investors, the milestone reinforces BD's strategy of expanding its advanced tissue regeneration franchise through clinically backed innovation rather than relying solely on new product launches. Management has identified advanced tissue regeneration as one of its fastest-growing platforms, with double-digit growth and multiple clinical trials underway to broaden Phasix Mesh into new indications, making successful PREVENT data and a planned FDA submission a potential long-term growth catalyst.

Likely Trend of BDX Stock Following the NewsFollowing the announcement of the news, BDX shares have traded flat. In the year-to-date period, shares of the company have lost 2.6% against the industry’s 5.1% increase. However, the S&P 500 has risen 12.2% in the same timeframe.

The PREVENT enrollment milestone strengthens BD's long-term growth outlook by expanding Phasix Mesh beyond hernia repair into the largely untapped incisional hernia prevention market, where no products are currently approved in the United States. Successful 24-month data could support an FDA submission, open a new commercial opportunity while reinforcing the company's evidence-driven innovation strategy. The development also aligns with management's broader focus on advanced tissue regeneration, which has been delivering double-digit growth and remains a key long-term growth platform supported by multiple clinical expansion programs.

BDX currently has a market capitalization of $51.69 billion.

Image Source: Zacks Investment Research

More on the NewsThe PREVENT trial represents a key milestone in BD's effort to expand the use of its Phasix Mesh beyond traditional hernia repair into incisional hernia prevention, an area with a significant unmet medical need following abdominal surgery. The study enrolled 477 patients across 32 clinical sites in the United States and Europe, making it the first large-scale randomized trial to evaluate prophylactic reinforcement with a resorbable mesh for this indication, where no products currently have regulatory approval.

According to Rian Seger, worldwide president of Surgery at BD, the trial builds on the company's long-standing expertise in abdominal wall surgery while generating clinical evidence that could broaden the use of regenerative technologies for patients at risk of post-surgical complications.

The trial is designed to evaluate Phasix Mesh in high-risk patients undergoing elective open midline abdominal surgery, with the goal of establishing robust clinical evidence for preventing incisional hernias. Patients will be followed through the study's primary endpoint at 24 months, while longer-term follow-up extending to five years will further assess safety and clinical outcomes.

Upon completion of the primary endpoint assessments, BD expects the findings to support a planned submission to the FDA, potentially paving the way for a label expansion into a new preventive surgical indication. The milestone also aligns with management's broader strategy, outlined during its fiscal third-quarter earnings call, of using multiple clinical programs to expand the advanced tissue regeneration platform into new indications as a long-term growth driver.

Advanced Tissue Regeneration Pipeline Extends Beyond PREVENTBeyond the PREVENT study, BD is advancing multiple clinical trials aimed at expanding its advanced tissue regeneration portfolio into new applications. Management said that the Phasix biomaterial platform remains one of the company's key long-term growth drivers, with several ongoing studies evaluating its use across additional indications beyond abdominal wall surgery. The company expects these evidence-generation efforts, alongside continued double-digit growth in the business, to strengthen its presence in regenerative surgery and support future commercial expansion.

Other NewsRecently, BD exited the third quarter of fiscal 2026 with better-than-expected results and solid top- and bottom-line results. Robust performances by all segments and both geographic regions were encouraging.

Apart from these, there were a few other developments during the recent period. BDX was awarded a Vizient Innovative Technology contract for the BD CentroVena One Insertion System.

The company launched the Elyra Thulium Fiber Laser System, thus expanding its kidney stone care portfolio. BD also announced a collaboration with Brazil-based pharmaceutical company EMS to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report)  West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.

Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.

Phasix Flat Mesh The study enrolled 477 patients across 32 sites in the United States and Europe, making it the first large, randomized study evaluating prophylactic reinforcement for incisional hernia prevention using a resorbable mesh, a common complication following abdominal surgery for which no products are currently approved.

"PREVENT reflects our commitment to extending the impact of advanced tissue regeneration into new areas of patient care," said Rian Seger, worldwide president of Surgery at BD. "By evaluating Phasix™ Mesh in hernia prevention, we are building on decades of innovation in abdominal wall surgery and generating evidence that could help broaden the role of regenerative technologies for patients at risk of post-surgical complications. We are grateful to the investigators, clinical sites and patients whose participation made this achievement possible."

The PREVENT trial aims to generate robust clinical evidence evaluating Phasix™ Mesh for the prevention of incisional hernia following elective open midline abdominal surgery in patients at high risk of developing a hernia.

Patients will continue to be followed through the study's primary endpoint at 24 months, with longer-term follow-up planned through five years to further evaluate safety and clinical outcomes. Following completion of the primary endpoint assessments, data from the study are expected to support a planned submission to the U.S. Food and Drug Administration as part of the regulatory pathway for this indication.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

3 Dividend Kings That Earn Their Crown Every QuarterBecton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations.

Chairman, Chief Executive Officer and President Tom Polen said the quarter was BD’s first full period operating as a focused medical technology company following the separation of its life sciences business. More than 90% of the portfolio delivered high-single-digit growth, he said, while several platforms posted double-digit gains.

Get BDX alerts:

Intuitive Surgical Gives Buying Opportunity Off Its 52 Week HighsAdjusted operating margin was 24.9%, while adjusted diluted earnings per share rose 4.9% to $3.23. The company raised the midpoint of its full-year adjusted EPS outlook and now expects earnings of $12.62 to $12.72 per share.

Growth Platforms Drive Broad-Based Performance BD cited double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration. The company also reported strong performance in peripheral vascular disease and Rowa pharmacy automation.

Healthcare Stocks With at Least 30 Years of Dividend IncreasesExecutive Vice President and Chief Financial Officer Vitor Roque said Medical Essentials revenue grew 3.2%, with strong U.S. performance in medication delivery solutions supported by share gains in vascular access management and utilization recovery following last year’s fluid shortage. Specimen management delivered high-single-digit growth, driven by share gains in the BD Vacutainer portfolio, improved supply and demand from customers working through competitor back orders.

Connected Care revenue rose 4.4%, led by double-digit growth in advanced patient monitoring and continued strength in consumables. Medication management solutions grew at a low-single-digit rate, supported by double-digit dispensing growth and Rowa pharmacy automation, though results were partly offset by a difficult comparison in Alaris capital sales.

BioPharma Systems revenue increased 5.2%, driven by double-digit biologics growth led by GLP-1 programs. Excluding vaccines, the segment grew in the mid-teens, Roque said. Interventional revenue rose 5.5%, with growth in oncology and peripheral vascular disease, while the urology and critical care business benefited from continued double-digit PureWick growth. Surgery was supported by double-digit gains in infection prevention and advanced tissue regeneration.

Polen said BD has signed approximately 100 agreements across novel and biosimilar GLP-1 programs. He also highlighted a collaboration with Brazilian pharmaceutical company EMS to launch a semaglutide therapy using BD’s Vystra injection pen.

Commercial Investments and Product Launches Management attributed part of its growth to commercial investments and a reallocation of sales resources toward higher-growth categories. Polen said investments in advanced patient monitoring contributed about 100 to 150 basis points to that platform’s growth rate during the quarter.

BD increased its U.S. advanced patient monitoring sales force by about 15%, Polen said. The company also expanded investments in the Veterans Affairs channel for PureWick and increased its U.S. peripheral intervention sales team by 15%.

During the quarter, BD launched or expanded several products, including the Liverty TIPS Stent Graft in Europe, the Elyra Thulium Fiber Laser System for kidney stone procedures, and the Acumen IQ plus finger cuff and Smart Pressure Controller for its HemoSphere Alta monitoring platform. The Acumen technologies are commercially available in the U.S. and Europe, according to the company.

Margins, Cash Flow and Capital Allocation Adjusted gross margin was 54.3% and adjusted operating margin was 24.9%, down 100 basis points and 130 basis points, respectively, from the prior year. Productivity gains and favorable mix were offset by approximately 110 basis points of tariff impact, as well as continued investment in selling and research and development activities.

Polen said BD generated approximately 8% gross productivity in its plants during the quarter, supported by plant consolidations, raw-material savings, waste reduction and improved efficiency on critical production lines. Service levels exceeded 90%, while back orders reached record lows, he said.

Year-to-date free cash flow rose 45% from the prior year to $1.7 billion, reflecting improved working capital and lower non-operating cash items, including Alaris remediation outlays. BD returned $3.1 billion to shareholders year to date, including about $2.3 billion in share repurchases and $0.9 billion in dividends. Net leverage ended the quarter at about 2.9 times, compared with the company’s long-term target of 2.5 times.

Updated Outlook and 2027 Considerations BD now expects fiscal 2026 revenue growth toward the high end of its low-single-digit FX-neutral range. Based on current spot rates, the company expects foreign exchange to provide approximately a 100-basis-point tailwind to reported revenue. It continues to expect adjusted operating margin of about 25%, including tariff effects, and an adjusted effective tax rate between 16% and 17%.

Looking ahead to fiscal 2027, Roque said BD continues to view low-single-digit revenue growth as a reasonable starting framework because the end of Alaris remediation is expected to create a 200-basis-point revenue headwind. He said the company expects “modest” earnings leverage from that revenue baseline, supported by pricing actions, BD Excellence productivity measures and capital allocation actions.

Polen said vaccine pressure in China appeared to be stabilizing and that BD expects to begin lapping the vaccine headwind in the next quarter. China represented about 4% of New BD revenue and could decline into the 3% range as other parts of the company grow faster, he said.

BD also announced that Mike Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, intends to retire after more than 20 years with the company. Peter Menziuso joined BD on June 1 as executive vice president and president of BD Interventional.

About Becton, Dickinson and Company (NYSE:BDX)Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Becton, Dickinson and Co (NYSE:BDX) on Thursday reported third-quarter adjusted earnings of $3.23 per share, beating the consensus of $3.14.

The medical technology company reported sales of $4.983 billion, surpassing the Wall Street estimate of $4.887 billion.

Sales jumped 5.4% year over year (+4.4 on constant currency).

The company said on its earnings call that the growth reflects broad-based growth across the portfolio and disciplined execution through a dynamic environment.

Revenue Growth Across Key Medical UnitsIn the Medication Delivery Solutions division, total revenue reached $1.164 billion, up 2.8%, driven by U.S. commercial execution and market share expansion in Vascular Access Management, despite headwinds from volume-based procurement in China.

Specimen Management revenue grew 8.7% to $511 million, lifted by market share gains in BD Vacutainer products and competitor supply disruptions.

Read Next

Additionally, Medication Management Solutions generated $915 million, up 3% behind double-digit dispensing momentum and strength in BD Rowa.

Patient Monitoring And Biopharma ExpandAdvanced Patient Monitoring revenue surged 10.9% to $309 million, supported by Smart Recovery products, growing adoption of Acumen IQ Cuff and Acumen IQ Sensor, and solid consumable demand.

Meanwhile, Biopharma systems achieved 6.6% growth to $670 million, driven by double-digit growth in Biologics due to continued strength in GLP-1 offerings, partially offsetting lower market demand for vaccine products.

Interventional Segment Delivers GainsPeripheral Intervention revenue rose 7.8% to $552 million, led by Oncology gains following the launch of the EnCor EnCompass Biopsy System and demand for the Rotarex Atherectomy System.

Urology & Critical Care revenue rose 4.2% to $440 million on double-digit PureWick adoption across home care settings, while Surgery revenue grew 7% to $422 million behind Infection Prevention and Advanced Tissue Regeneration.

“Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence,” said Tom Polen, chairman, CEO and president of BD.

“We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value,” Polen said.

Citing broad-based momentum, the company revised its full-year fiscal 2026 adjusted earnings per share guidance from $12.52-$12.72 to $12.62-$12.72, compared to the consensus of $12.61.

BDX Price Action: Becton Dickinson shares were up 3.91% at $177.33 at the time of publication on Thursday, according to Benzinga Pro data.

Read Next

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Becton Dickinson (BDX - Free Report) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $3.68 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +2.87%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.77 per share when it actually produced earnings of $2.9, delivering a surprise of +4.69%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Becton Dickinson, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $4.98 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.81%. This compares to year-ago revenues of $5.51 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Becton Dickinson shares have lost about 12.1% since the beginning of the year versus the S&P 500's gain of 12.8%.

What's Next for Becton Dickinson?While Becton Dickinson has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Becton Dickinson was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.11 on $5.13 billion in revenues for the coming quarter and $12.53 on $19.34 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 15% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Staar Surgical (STAA - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 12.

This maker of implantable lenses is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +400%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Staar Surgical's revenues are expected to be $90.77 million, up 104.8% from the year-ago quarter.

Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.

"We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence. We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value."

Recent Business Highlights

Medical Essentials: Awarded a Vizient Innovative Technology contract for the BD® CentroVena One™ Insertion System, validating CentroVena One™ Insertion System as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety. BioPharma Systems: Announced a collaboration with EMS, one of Brazil's leading pharmaceutical companies, to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra™ Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes. Interventional:  Launched the Elyra™ Thulium Fiber Laser System, expanding BD's kidney stone care portfolio with a system designed to help urology teams enhance efficiency, versatility and procedural workflow. BD named to TIME's 2026 List of America's Best Companies. BD issued its Fiscal Year 2025 Together We Advance Corporate Sustainability Report. Basis of Presentation— Continuing Operations

On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.

Third Quarter Fiscal 2026 Operating Results

(Millions of dollars, except per share amounts)

Three Months Ended June 30,

Reported
Change 

Foreign Currency
Neutral Change1

2026

2025

Revenues

$                4,983

$                4,726

5.4 %

4.4 %

Reported Diluted Earnings per Share

$                  1.64

$                  1.57

4.5 %

3.8 %

Adjusted Diluted Earnings per Share1

$                  3.23

$                  3.08

4.9 %

3.9 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.

Geographic Results

Revenues (Millions of dollars)

Three Months Ended June 30,

Reported
Change

Foreign Currency
Neutral Change1

2026

2025

United States

$                3,081

$                2,882

6.9 %

6.9 %

International

$                1,902

$                1,844

3.2 %

0.6 %

Total Revenues

$                4,983

$                4,726

5.4 %

4.4 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.

Segment Results

Revenues (Millions of dollars)

Three Months Ended June 30,

Reported
Change

Foreign Currency
Neutral Change1

2026

2025

Medical Essentials2

$                 1,675

$                 1,602

4.5 %

3.2 %

Connected Care2

$                 1,224

$                 1,166

4.9 %

4.4 %

BioPharma Systems2

$                    670

$                    629

6.6 %

5.2 %

Interventional2

$                 1,414

$                 1,328

6.4 %

5.5 %

Total Revenues

$                 4,983

$                 4,726

5.4 %

4.4 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables. 

2Effective October 1, 2025, the company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the company's product and service offerings. Subsequent to the spin-off of the company's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

Full Year Fiscal 2026 Guidance

The company updates its full year fiscal 2026 guidance as follows; expects revenue growth toward the high end of its range and raises the midpoint of adjusted diluted EPS guidance.

Updated New BD Guidance

as of August 6, 2026

Prior New BD Guidance

as of May 7, 2026

GAAP Revenue Growth

Low single-digit plus

Low single-digit plus

Revenue Growth (FXN)

Low single-digit

Low single-digit

Adjusted Diluted EPS

$12.62 to $12.72

$12.52 to $12.72

BD's guidance for full year fiscal 2026 reflects numerous assumptions that could affect its business, based on the information management has reviewed as of this date. Management will discuss its guidance and several of its assumptions on its third fiscal quarter earnings call. 

The company's expected adjusted diluted EPS for fiscal 2026 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our revenue growth for our 2026 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying revenue performance for our 2026 fiscal year in relation to our underlying 2025 fiscal year performance.

Conference Call and Presentation Materials
BD will host an audio webcast today for the public, investors, analysts and news media to discuss its third quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors, at 8 a.m. (ET) Thursday, August 6, 2026. Accompanying slides will be available on BD's website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-688-9445 (domestic) and 402-220-1371 (international) through the close of business on Thursday, August 13, 2026. A confirmation number is not needed to access the replay.

Non-GAAP Financial Measures/Financial Tables
This press release contains certain non-GAAP financial measures. These include revenue growth rates on a currency-neutral basis, adjusted diluted earnings per share and free cash flow. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results, and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. 

We present adjusted diluted earnings per share for the third quarter and the first nine months of fiscal year 2026, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction costs, separation-related costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, certain pension settlement costs, and the impact of the extinguishment of debt. 

We also present revenue growth rates for the third quarter and the first nine months of fiscal year 2026 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior period. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods. 

We also present free cash flow for the first nine months of fiscal year 2026 over the corresponding prior period, which is net cash provided by continuing operating activities less capital expenditures, to provide a view of the Company's ability to generate cash for use in acquisitions and other investing and financing activities. Free cash flow is not a measure of cash available for discretionary expenditures given that we have certain non-discretionary obligations such as debt service that are not deducted from the measure. We believe the presentation of results of free cash flow in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior period.

New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD. 

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

***

This press release and accompanying audio webcast on August 6, 2026 contain certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and performance, including, but not limited to, statements relating to future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including volatility resulting from the imposition of (and changing policies around) tariffs enacted by the U.S. government (and related countermeasures by non-U.S. governments), or our ability to mitigate the impact of such tariffs, including developments regarding refunds of certain tariffs and/or the collection of remaining refunds of certain tariffs; import or export licensing requirements and other governmental restrictions; reductions in U.S. government funding for healthcare, disruptions in global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products; inflationary pressures, currency and interest rate fluctuations, global oil prices and increased borrowing costs; conditions in international markets, including geopolitical developments such as the continuation and/or escalation of evolving situations in Iran and the Middle East region (which could result in continued disruption of transportation lanes and global energy supplies, as well as increases in global oil prices and adversely affect our supply chain costs, ability to source raw materials and components and our ability to deliver product to customers), Ukraine and Asia; competitive factors, including changing customer and patient preferences and requirements, such as decreased demand for our products as a result of changes to U.S. federal and state policies (such as for pharmaceutical products and vaccines), and increased demand for products utilizing evolving technologies (including emerging technologies utilizing artificial intelligence ("AI")), as well as new products or novel medical therapies introduced by competitors; changes in research and development efforts, investment or suspension by pharmaceuticals companies with regard to vaccine development; changes in reimbursement practices and coverage policies and third-party payer cost containment measures and health insurance coverage levels and costs; decreases or delays in purchases of our products due to reduced research and development spending; product efficacy or safety concerns and related regulatory actions, changes to the labeled indications or permitted uses of our products, non-compliance with applicable regulatory requirements regarding our products, including marketing authorization, registration, quality system and manufacturing requirements (including as a result of product modifications), or other factors that could result in product recalls, field actions, lost revenue, restrictions on our ability to continue selling existing products or commercialize new products (including limitations on future product clearances or approvals and the imposition of civil penalties); increased exposure to product liability or other claims and damage to our reputation (including products we acquire through acquisitions); changes to legislation or regulations that may impact U.S. or foreign healthcare systems, changes in medical or clinical practices or in customer and patient preferences, efforts to improve compliance of healthcare practitioners, potential cuts or freezes in healthcare spending and/or governmental or private measures to contain healthcare costs, such as China's volume-based procurement tender process or changes in pricing and reimbursement policies, which could result in reduced demand for our products or downward pricing pressure; policy and regulatory changes that may be implemented by the U.S. government, including the further elimination, downsizing and/or reduced funding of certain government agencies and programs, as well as further changes in the policy positions of such agencies (including those related to pharmaceutical products and vaccines); other new or changing laws and regulations impacting our business, including changes in tax laws, new and changing environmental laws and regulations (such as those related to sustainability, climate change or materials of concern) and new and changing cybersecurity, AI or privacy laws; other changes in laws impacting international trade or anti-corruption and bribery, or changes in reporting requirements or enforcement practices with respect to such laws; the adverse impact on our business or products of past, current or future information and technology system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, and any investigations, legal proceedings, liability, expense or reputational damage arising in connection with any such events; any adverse impact related to the development, deployment and use of AI in our products and business operations; labor disruptions; our suppliers' ability to provide products needed for our operations and BD's ability to maintain favorable supplier arrangements and relationships; increases in raw material, component, labor, duties, freight, energy and other production costs and their effect on, among other things, the cost of producing BD's products; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations; risks relating to our overall indebtedness; the possible impact of natural disasters and public health crises on our business and the global healthcare system, which could decrease demand for our products, disrupt our operations or the operations of our customers and companies within our supply chain, or increase transportation costs; interruptions in our manufacturing or sterilization processes or those of our third-party providers, including any restrictions placed on the use of ethylene oxide for sterilization; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the overall timing of the replacement or remediation of the BD Alaris™ Infusion System and return to market in the U.S., which may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA; our ability to achieve our projected level or mix of product sales; our ability to achieve or maintain growth of our portfolio; our ability to successfully integrate any businesses we acquire; uncertainties of litigation, investigations, regulatory actions, subpoenas, settlements, fines, penalties and/or other sanctions (as described in BD's filings with the Securities and Exchange Commission (the "SEC")); the issuance of new or revised accounting standards; our ability to execute our New BD strategy, Excellence Unleashed, as expected; and other factors discussed in BD's filings with the SEC. Tariff commentary is based on tariff policies in effect as of August 5, 2026. International trade policies, trade restrictions and tariffs (and related countermeasures and developments regarding refunds of certain tariffs) are rapidly evolving and there can be no assurance as to how the landscape may change and what the ultimate impact on our guidance and results of operations will be. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contacts:
Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
Media: Matt Marcus, VP, Public Relations - [email protected] 

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Three Months Ended June 30,

2026

2025

% Change

Revenues

$

4,983

$

4,726

5.4

Cost of products sold

2,668

2,491

7.1

Selling and administrative expense

1,261

1,163

8.4

Research and development expense

258

230

12.0

Integration, restructuring and transaction expense

89

96

(6.9)

Other operating expense, net

44

7

544.7

Total Operating Costs and Expenses

4,320

3,986

8.4

Operating Income

663

739

(10.3)

Interest expense

(132)

(152)

(13.4)

Interest income

4

4

(15.8)

Other income (expense), net

19

(22)

183.9

Income from Continuing Operations Before Income Taxes

554

569

(2.7)

Income tax provision

102

118

(13.2)

Net Income from Continuing Operations

451

451

0.1

(Loss) Income from Discontinued Operations, Net of Tax

(74)

123

(159.8)

Net Income

$

377

$

574

(34.3)

Basic Earnings Per Share

Income from Continuing Operations

$

1.64

$

1.57

4.5

(Loss) Income from Discontinued Operations

(0.27)

0.43

(162.8)

Basic Earnings per Share

$

1.37

$

2.00

(31.5)

Diluted Earnings Per Share

Income from Continuing Operations

$

1.64

$

1.57

4.5

(Loss) Income from Discontinued Operations

(0.27)

0.43

(162.8)

Diluted Earnings per Share

$

1.37

$

2.00

(31.5)

Average Shares Outstanding (in thousands)

Basic

274,788

287,170

Diluted

275,158

287,223

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Nine Months Ended June 30,

2026

2025

% Change

Revenues

$

14,183

$

13,539

4.8

Cost of products sold

7,662

7,646

0.2

Selling and administrative expense

3,703

3,435

7.8

Research and development expense

742

706

5.1

Integration, restructuring and transaction expense

729

277

162.9

Other operating expense, net

122

70

74.9

Total Operating Costs and Expenses

12,958

12,134

6.8

Operating Income

1,225

1,405

(12.8)

Interest expense

(434)

(458)

(5.1)

Interest income

16

31

(47.4)

Other income (expense), net

97

(72)

234.4

Income from Continuing Operations Before Income Taxes

904

906

(0.2)

Income tax provision

179

151

18.5

Net Income from Continuing Operations

725

755

(4.0)

(Loss) Income from Discontinued Operations, Net of Tax

(276)

430

(164.3)

Net Income

$

449

$

1,185

(62.1)

Basic Earnings Per Share

Income from Continuing Operations

$

2.59

$

2.62

(1.1)

(Loss) Income from Discontinued Operations

(0.99)

1.49

(166.4)

Basic Earnings per Share

$

1.60

$

4.11

(61.1)

Diluted Earnings Per Share

Income from Continuing Operations

$

2.58

$

2.62

(1.5)

(Loss) Income from Discontinued Operations

(0.98)

1.49

(165.8)

Diluted Earnings per Share

$

1.59

$

4.10

(61.2)

Average Shares Outstanding (in thousands)

Basic

280,332

287,997

Diluted

281,603

288,693

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited; Amounts in millions)

June 30, 2026

September 30, 2025

Assets

Cash and equivalents

$

708

$

567

Restricted cash

155

210

Short-term investments

1

8

Trade receivables, net

2,364

2,396

Inventories

3,316

3,149

Prepaid expenses and other

1,595

1,379

Current assets of discontinued operations

—

1,545

Total Current Assets

8,139

9,255

Property, plant and equipment, net

6,083

6,383

Goodwill and other intangibles, net

33,964

35,190

Other assets

2,546

2,383

Noncurrent assets of discontinued operations

—

2,114

Total Assets

$

50,731

$

55,325

Liabilities and Shareholders' Equity

Current debt obligations

$

3,297

$

1,559

Other current liabilities

6,107

6,106

Current liabilities of discontinued operations

—

648

Long-term debt

13,511

17,620

Long-term employee benefit obligations

1,005

1,027

Deferred income taxes and other liabilities

2,394

2,632

Noncurrent liabilities of discontinued operations

—

342

Shareholders' equity

24,416

25,390

Total Liabilities and Shareholders' Equity

$

50,731

$

55,325

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; Amounts in millions)

Nine Months Ended June 30,

2026

2025

Operating Activities

Net income

$

449

$

1,185

Less: (Loss) income from discontinued operations, net of tax

(276)

430

Income from continuing operations, net of tax

725

755

Depreciation and amortization

1,697

1,706

Change in operating assets and liabilities and other, net

(319)

(883)

    Net Cash Provided by Continuing Operating Activities

2,104

1,578

Investing Activities

Capital expenditures

(376)

(383)

Maturities and sales of investments

27

408

Acquisitions, net of cash acquired and adjustments

(22)

13

Other, net

(192)

(267)

    Net Cash Used for Continuing Investing Activities

(563)

(229)

Financing Activities

Change in short-term debt

37

133

Proceeds from long-term debt

704

—

Distribution from spin-off entity, net

3,857

—

Payments of debt

(2,696)

(1,208)

Repurchases of common stock

(2,250)

(750)

Dividends paid

(875)

(899)

Other, net

(70)

(83)

    Net Cash Used for Continuing Financing Activities

(1,293)

(2,807)

Discontinued Operations

Net cash (used for) provided by operating activities

(198)

498

Net cash used for investing activities

(40)

(96)

Net cash provided by (used for) financing activities

71

(8)

    Net Cash (Used for) Provided by Discontinued Operations

(167)

395

Effect of exchange rate changes on cash and equivalents and restricted cash

5

(2)

    Net increase (decrease) in cash and equivalents and restricted cash

86

(1,065)

Opening Cash and Equivalents and Restricted Cash

777

1,792

Closing Cash and Equivalents and Restricted Cash

$

863

$

727

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended June 30,

(Unaudited; Amounts in millions)

United States

International

Total

% Change

% Change

2026

2025

% Change

2026

2025

FX Impact

Reported

FXN

2026

2025

FX Impact

Reported

FXN

Medical Essentials(1)

Medication Delivery Solutions

$

720

$

680

5.9

$

444

$

452

$

13

(1.8)

(4.7)

$

1,164

$

1,132

$

13

2.8

1.6

Specimen Management

274

240

14.0

237

230

8

3.1

(0.2)

511

470

8

8.7

7.0

Total

$

994

$

920

8.0

$

681

$

682

$

21

(0.1)

(3.2)

$

1,675

$

1,602

$

21

4.5

3.2

Connected Care(1)

Medication Management Solutions

$

737

$

709

3.9

$

178

$

179

$

6

(0.4)

(4.0)

$

915

$

888

$

6

3.0

2.3

Advanced Patient Monitoring

189

176

7.4

120

102

(1)

17.1

17.8

309

278

(1)

10.9

11.2

Total

$

926

$

885

4.6

$

297

$

281

$

6

5.9

3.9

$

1,224

$

1,166

$

6

4.9

4.4

BioPharma Systems(1)(2)

$

204

$

178

14.2

$

467

$

451

$

9

3.6

1.6

$

670

$

629

$

9

6.6

5.2

Interventional(1)

Peripheral Intervention

$

294

$

271

8.4

$

258

$

241

$

9

7.2

3.5

$

552

$

512

$

9

7.8

6.1

Urology and Critical Care

357

334

7.1

82

88

—

(6.7)

(6.9)

440

422

—

4.2

4.2

Surgery

306

294

4.3

116

101

3

15.0

11.7

422

395

3

7.0

6.2

Total

$

957

$

898

6.6

$

457

$

430

$

12

6.2

3.3

$

1,414

$

1,328

$

12

6.4

5.5

Total Revenues from Continuing Operations

$

3,081

$

2,882

6.9

$

1,902

$

1,844

$

48

3.2

0.6

$

4,983

$

4,726

$

48

5.4

4.4

(1)

Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the Company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

(2)

The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Nine Months Ended June 30,

(Unaudited; Amounts in millions)  

United States

International

Total

% Change

% Change

2026

2025

% Change

2026

2025

FX Impact

Reported

FXN

2026

2025

FX Impact

Reported

FXN

Medical Essentials(1)

Medication Delivery Solutions

$

2,124

$

2,060

3.1

$

1,331

$

1,313

$

56

1.4

(2.9)

$

3,455

$

3,373

$

56

2.4

0.8

Specimen Management

772

721

7.2

690

667

32

3.5

(1.2)

1,463

1,387

32

5.4

3.1

Total

$

2,897

$

2,781

4.2

$

2,021

$

1,979

$

88

2.1

(2.3)

$

4,918

$

4,760

$

88

3.3

1.5

Connected Care(1)

Medication Management Solutions

$

2,076

$

2,030

2.3

$

502

$

470

$

27

6.8

1.2

$

2,578

$

2,500

$

27

3.1

2.1

Advanced Patient Monitoring

547

490

11.7

350

317

5

10.6

9.1

897

806

5

11.3

10.7

Total

$

2,623

$

2,520

4.1

$

852

$

787

$

31

8.3

4.4

$

3,475

$

3,307

$

31

5.1

4.2

BioPharma Systems(1)(2)

$

532

$

431

23.4

$

1,157

$

1,191

$

41

(2.8)

(6.2)

$

1,689

$

1,622

$

41

4.1

1.6

Interventional(1)

Peripheral Intervention

$

839

$

793

5.8

$

713

$

673

$

29

6.0

1.6

$

1,552

$

1,466

$

29

5.9

3.9

Urology and Critical Care

1,047

962

8.8

250

249

5

0.4

(1.8)

1,297

1,211

5

7.1

6.6

Surgery

919

885

3.8

333

288

13

15.8

11.1

1,252

1,173

13

6.8

5.6

Total

$

2,805

$

2,640

6.2

$

1,296

$

1,209

$

48

7.2

3.2

$

4,101

$

3,849

$

48

6.5

5.3

Total Revenues from Continuing Operations

$

8,857

$

8,372

5.8

$

5,326

$

5,166

$

208

3.1

(0.9)

$

14,183

$

13,539

$

208

4.8

3.2

(1)

Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the Company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

(2)

The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

Three Months Ended June 30,

(Unaudited)

Three Months Ended June 30,

2026

2025

Change

Translational FX

FXN
Change

Change %

FXN
Change %

Reported Diluted Earnings per Share from Continuing Operations

$

1.64

$

1.57

$

0.07

$

0.01

$

0.06

4.5

%

3.8

%

Purchase accounting adjustments ($363 million and $376 million pre-tax, respectively) (1)

1.32

1.31

—

Integration costs ($41 million and $37 million pre-tax, respectively) (2)

0.15

0.13

—

Restructuring costs ($48 million and $57 million pre-tax, respectively) (2)

0.18

0.20

0.03

Transaction costs ($1 million pre-tax) (3)

—

0.01

—

Separation-related items ($32 million pre-tax) (4) 

0.12

—

—

Product, litigation, and other items ($53 million and $44 million pre-tax, respectively) (5)

0.19

0.15

—

Tax impact of specified items and other tax related (($101) million and $(82) million, respectively)

(0.37)

(0.29)

—

Adjusted Diluted Earnings per Share from Continuing Operations

$

3.23

$

3.08

$

0.15

$

0.03

$

0.12

4.9

%

3.9

%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities.

(3)

Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the three months ended June 30, 2026 reflects charges to adjust the estimate of certain future product remediation costs, various legal matters, and pension settlement costs. The amount for the three months ended June 30, 2025 reflects a charge of $30 million recorded to Other income (expense), net, related to pension settlement costs.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

Nine Months Ended June 30,

(Unaudited)

Nine Months Ended June 30,

2026

2025

Change

Translational FX

FXN
Change

Change %

FXN
Change %

Reported Diluted Earnings per Share from Continuing Operations

$

2.58

$

2.62

$

(0.04)

$

0.05

$

(0.09)

(1.5)

%

(3.4)

%

Purchase accounting adjustments ($1.113 billion and $1.481 billion pre-tax, respectively) (1)

3.95

5.13

0.01

Integration costs ($123 million and $87 million pre-tax, respectively) (2)

0.44

0.30

—

Restructuring costs ($605 million and $185 million pre-tax, respectively) (2)

2.15

0.64

0.05

Transaction costs ($5 million pre-tax) (3)

—

0.02

—

Separation-related items ($73 million pre-tax) (4)

0.26

—

—

Product, litigation, and other items ($193 million and $255 million pre-tax, respectively) (5)

0.68

0.88

—

Impacts of debt extinguishment (($122) million pre-tax)

(0.43)

—

—

Tax impact of specified items and other tax related (($292) million and ($273) million, respectively)

(1.04)

(0.95)

—

Adjusted Diluted Earnings per Share from Continuing Operations

$

8.59

$

8.65

$

(0.06)

$

0.11

$

(0.17)

(0.7)

%

(2.0)

%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities. Restructuring costs for the nine months ended June 30, 2026 reflect non-cash asset impairment charges of $450 million across all reportable segments based upon the Company's commitment to exit certain operational activities and projects which no longer align with and facilitate its current operational strategy, Excellence Unleashed. These exit actions are aimed at simplifying the Company's operations and aligning resources behind its most value-creating platforms. The impairment charges are primarily reflected as decreases of $238 million within Property, plant and equipment, net, and $134 million within Goodwill and other intangibles, net, on the Company's June 30, 2026 condensed consolidated balance sheet.

(3)

Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the nine months ended June 30, 2026 reflects charges of $57 million recorded to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $75 million recorded to Other operating expense, net, related to various legal matters, and a charge of $43 million recorded to Other income (expense), net, related to pension settlement costs. The amount for the nine months ended June 30, 2025 reflects charges of $98 million recorded to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $64 million recorded to Other operating expense, net, related to various legal matters, and a charge of $30 million recorded to Other income (expense), net, related to pension settlement costs.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION FROM NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES TO FREE CASH FLOW

Nine Months Ended June 30,

(Unaudited)

A

B

C=A-B

D=C/B

2026

2025

Change

% Change

Net Cash Provided by Continuing Operating Activities

$

2,104

$

1,578

$

526

33.3

%

Capital Expenditures

(376)

(383)

7

(1.7)

%

Free Cash Flow

$

1,728

$

1,195

$

532

44.6

%

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2026 GUIDANCE RECONCILIATION

Full Year FY2025

Full Year FY2026 Guidance

($ in millions)

% Change

BDX Reported Revenues from Continuing Operations

$

18,544

FY2026 Reported Revenue Growth

Low single-digit plus

Illustrative Foreign Currency (FX) Impact

~+100 basis points

FY2026 Revenue Growth (FXN)

Low single-digit

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2026 GUIDANCE RECONCILIATION CONTINUED

Full Year FY 2026 Guidance

Full Year FY2025

Total Company

Reported Diluted Earnings per Share from Continuing Operations

$

3.81

Purchase accounting adjustments ($1.865 billion pre-tax) (1)

6.46

Integration costs ($127 million pre-tax) (2)

0.44

Restructuring costs ($270 million pre-tax) (2)

0.93

Transaction costs ($6 million pre-tax) (3)

0.02

Separation-related items ($3 million pre-tax) (4)

0.01

Product, litigation, and other items ($506 million pre-tax) (5)

1.75

Tax impact of specified items and other tax related (($443) million)

(1.54)

Adjusted Diluted Earnings per Share from Continuing Operations

$

11.90

$12.62 to $12.72

Reported % Change

+6.1% to +6.9%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities.

(3)

Represents transaction costs incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 reflects charges of $98 million to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $297 million to Other operating expense, net, related to product liability and certain other legal matters, and charges of $38 million to Other expense, net, related to pension settlement costs.

SOURCE BD (Becton, Dickinson and Company)

Wall Street analysts forecast that Becton Dickinson (BDX - Free Report) will report quarterly earnings of $3.14 per share in its upcoming release, pointing to a year-over-year decline of 14.7%. It is anticipated that revenues will amount to $4.89 billion, exhibiting a decrease of 11.2% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

Given this perspective, it's time to examine the average forecasts of specific Becton Dickinson metrics that are routinely monitored and predicted by Wall Street analysts.

Analysts expect 'Revenues- Interventional' to come in at $1.39 billion. The estimate indicates a year-over-year change of +4.9%.

The consensus estimate for 'Revenues- Interventional- Surgery' stands at $417.50 million. The estimate indicates a change of +5.7% from the prior-year quarter.

It is projected by analysts that the 'Revenues- Interventional- Peripheral Intervention' will reach $528.50 million. The estimate indicates a year-over-year change of +3.2%.

Analysts predict that the 'Revenues- Interventional- Urology and Critical Care' will reach $447.64 million. The estimate indicates a change of +6.1% from the prior-year quarter.

Analysts' assessment points toward 'Revenues- Connected Care- Medication Management Solutions- International' reaching $178.72 million. The estimate points to a change of -0.2% from the year-ago quarter.

The combined assessment of analysts suggests that 'Revenues- Connected Care- Medication Management Solutions- United States' will likely reach $711.11 million. The estimate points to a change of +0.3% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Interventional- Peripheral Intervention- United States' will reach $282.52 million. The estimate points to a change of +4.3% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Revenues- Interventional- Urology and Critical Care- United States' of $358.22 million. The estimate points to a change of +7.3% from the year-ago quarter.

The average prediction of analysts places 'Revenues- Interventional- United States' at $947.23 million. The estimate indicates a change of +5.5% from the prior-year quarter.

According to the collective judgment of analysts, 'Revenues- Interventional- Surgery- International' should come in at $111.26 million. The estimate points to a change of +10.2% from the year-ago quarter.

Based on the collective assessment of analysts, 'Revenues- Interventional- Peripheral Intervention- International' should arrive at $249.73 million. The estimate indicates a year-over-year change of +3.6%.

Analysts forecast 'Revenues- Interventional- Urology and Critical Care- International' to reach $90.75 million. The estimate points to a change of +3.1% from the year-ago quarter.

View all Key Company Metrics for Becton Dickinson here>>>

Shares of Becton Dickinson have demonstrated returns of +9.4% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #4 (Sell), BDX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

 Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, today announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes.

The BD Vystra™ Injection Pen platform Global demand for GLP‑1 therapies has highlighted the critical need for delivery systems that enable safe, accurate, and consistent dosing for patients. Many patients face challenges with ease of use, confidence with self‑injection and adherence to treatment, making intuitive and reliable delivery solutions increasingly important.

EMS's semaglutide utilizes BD's established injection pen platform, which features an intuitive design built for ease of use. The BD Vystra™ Injection Pen platform reflects BD's deep expertise in drug delivery systems design and manufacturing, supporting scalable solutions that can help meet rising demand for injectable therapies.

"BD's partnership with EMS introduces a critical treatment option backed by scalable, patient-centric delivery technology," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection."

"Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil," said Gabriel Sanchez, Vice President of EMS. "By co-creating with BD, we're able to provide solutions that meet the needs of our clinicians and patients alike."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X   or Instagram @becton_dickinson.

About EMS
EMS is one of Brazil's leading pharmaceutical companies, with more than 60 years of experience developing and delivering innovative, high-quality therapies. The company operates across prescription medicines, generics and OTC, with a growing global footprint spanning more than 60 countries. EMS continues to invest in advanced manufacturing and R&D, including peptide capabilities to support GLP 1 therapies for obesity and type 2 diabetes.

SOURCE BD (Becton, Dickinson and Company)

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.

Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD's Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. Prior to joining BD in 2005, Garrison held various roles across R&D and marketing within the MedTech industry.

"Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions," said Tom Polen, Chairman, CEO and President of BD. "He has built strong teams, developed exceptional leaders and helped position our business for the future. We are grateful for Mike's leadership, partnership and many contributions to BD, and we wish him well in his retirement."

Garrison will remain in his role through the end of the fiscal year. A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Polen, streamlining the operating model and reflecting the segment's strategic importance as a growth driver.

"It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world," Garrison said. "I will always value the people, purpose and impact that have made my time at BD so meaningful, and I look forward to seeing the company continue to advance the future of care."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)